Herbs (Global Traditional) · Traditional Chinese Medicine
Coptis (Coptis chinensis) (Coptis chinensis)
Strong Evidencebotanical
Hermetica Superfood Encyclopedia
Coptis chinensis is a traditional Chinese medicinal herb containing berberine as its primary bioactive alkaloid. Berberine exhibits anti-inflammatory and hepatoprotective effects by inhibiting pro-inflammatory cytokines and modulating liver enzyme activity.
Coptis chinensis, commonly known as Coptis or Huang Lian, is a perennial herbaceous plant in the Ranunculaceae family native to China, with its rhizome (Coptidis Rhizoma) used medicinally. The rhizome is harvested and processed into powder, pills, decoctions, or tablets, often with wine, ginger juice, or Evodia rutaecarpa for specific therapeutic effects.
Current research on Coptis chinensis lacks human clinical trials, RCTs, or meta-analyses, with evidence limited to preclinical studies in cell cultures and animal models. Animal studies demonstrate anti-inflammatory and hepatoprotective effects, but no PubMed PMIDs for human trials are available in the current research.
No clinically studied dosage ranges for human use are available. Animal studies used varying doses showing dose-dependent effects, but human equivalents are not specified. Traditional forms include decoctions or powders without standardized dosing. Consult a healthcare provider before starting any new supplement.
Coptis chinensis (Huang Lian) is utilized as a medicinal herb rather than a food source, so conventional macronutrient profiling (carbohydrates, fats, protein) is not clinically relevant at typical therapeutic doses (1.5–10 g dried rhizome/day in traditional practice). Its pharmacological value derives from its rich alkaloid and bioactive compound content: **Primary Bioactive Alkaloids (collectively 5–8% of dried rhizome weight):** • Berberine: 4.0–7.5% of dried rhizome (the dominant and most studied alkaloid; typical concentrations ~50–90 mg/g depending on cultivar, harvest time, and processing) • Coptisine: 0.5–2.0% of dried rhizome • Palmatine: 0.5–1.5% of dried rhizome • Jatrorrhizine: 0.2–0.8% of dried rhizome • Epiberberine: 0.3–1.0% of dried rhizome • Columbamine: trace to 0.3% • Magnoflorine: trace amounts **Other Bioactive Compounds:** • Ferulic acid and other phenolic acids (minor amounts) • Lignans (woorenoside, etc.): trace quantities • Polysaccharides: present in the rhizome matrix, though not well-quantified for immunomodulatory activity • Organic acids including chlorogenic acid: trace amounts • Small amounts of volatile oils **Mineral Content (approximate, per dried rhizome):** • Potassium, calcium, magnesium, iron, manganese, and zinc are present in small quantities typical of plant rhizomes, but are not considered nutritionally significant at medicinal doses **Fiber & Carbohydrates:** • Crude fiber and starch are present in the dried rhizome but are not relevant at therapeutic doses **Bioavailability Notes:** • Berberine has notoriously low oral bioavailability (~5% or less in humans) due to extensive first-pass metabolism by CYP2D6, CYP1A2, and CYP3A4, poor intestinal absorption, and P-glycoprotein-mediated efflux • Gut microbiota convert berberine to dihydroberberine in the intestinal lumen, which is absorbed ~5-fold more efficiently and then re-oxidized to berberine in enterocytes • Berberine undergoes significant enterohepatic recirculation, which extends its effective half-life • Co-administration with P-glycoprotein inhibitors or lipid-based formulations can enhance berberine bioavailability • Coptisine and palmatine share similar bioavailability challenges as isoquinoline alkaloids • Traditional decoction preparation (boiling in water for 15–30 minutes) efficiently extracts water-soluble alkaloids; berberine extraction yield increases with decoction time up to a plateau • The Chinese Pharmacopoeia (2020 edition) requires a minimum berberine hydrochloride content of 5.5% in quality Coptis chinensis rhizome
Berberine, the main alkaloid in Coptis chinensis, inhibits nuclear factor-kappa B (NF-κB) signaling pathways, reducing production of inflammatory cytokines including IL-1β, TNF-α, and IL-6. The compound also modulates liver enzyme activity by protecting hepatocytes from oxidative stress and reducing inflammatory cascade activation. Berberine additionally affects AMPK (adenosine monophosphate-activated protein kinase) pathways, contributing to its hepatoprotective mechanisms.
Current evidence for Coptis chinensis comes primarily from animal studies rather than human clinical trials. Rat models of arthritis showed significant reductions in inflammatory markers when treated with Coptis extracts. Cholestasis studies in rats demonstrated decreased liver enzymes (ALT and AST) and reduced bilirubin levels compared to control groups. Human clinical data remains limited, with most research focusing on berberine as an isolated compound rather than whole Coptis preparations.
Coptis chinensis is generally well-tolerated but can cause gastrointestinal upset including nausea and diarrhea at higher doses. Berberine may interact with medications metabolized by cytochrome P450 enzymes, particularly affecting blood sugar medications and increasing hypoglycemia risk. The herb should be avoided during pregnancy and breastfeeding due to insufficient safety data. Individuals taking anticoagulant medications should consult healthcare providers as berberine may enhance blood-thinning effects.
